Highest-materiality recent filing
Quest Diagnostics reports unauthorized access to Quanum LSM system; some patient records accessed
On October 21, 2026, Quest learned of unauthorized access to its Quanum LSM system, which clients use to place test orders and receive and look up results.
Quest Diagnostics Q3 revenue $3.10B up 10%; adjusted EPS $3.00 up 15.4%; raises FY2026 guidance
Q3 net revenues $3.097B vs $2.816B; Diagnostic Information Services revenue $3.035B, up 10.2% YoY.
Quest Diagnostics EVP Catherine Doherty to retire July 2027, shifts to new EVP role Nov 1, 2026
Catherine T. Doherty will retire in July 2027; effective November 1, 2026 she moves to Executive Vice President covering health systems, the Corewell Health joint venture, and Project Nova.
Quest Diagnostics Q2 revenue up 10.2% to $3.04B; raises FY2026 guidance
Q2 revenue $3.04B (+10.2% YoY), organic growth 10.0%.
All 11 director nominees elected; Timothy M. Ring received 81.9M for, 12.0M against (lowest support).
Quest Diagnostics issues $500M of 5.000% senior notes due 2036
$500M aggregate principal, 5.000% coupon, maturity June 30, 2036.
Quest Diagnostics prices $500M of 5.000% senior notes due 2036
$500M aggregate principal of 5.000% senior notes due 2036 priced under shelf registration.
Quest Diagnostics Q1 revenue $2.90B (+9.2%), raises FY2026 EPS and revenue guidance
Reported diluted EPS $2.24 (+15.5%); adjusted diluted EPS $2.50 (+13.1%).
Quest Diagnostics elects former Walgreens CEO Timothy Wentworth to board
Elected Timothy Wentworth, former CEO of Walgreens Boots Alliance, as director effective March 9, 2026.
Quest Diagnostics Q4 rev $2.81B (+7.1%), adj EPS $2.42 (+8.5%); raises dividend 7.5%
FY2025 revenue $11.04B (+11.8%), reported EPS $8.75 (+13.8%), adjusted EPS $9.85 (+10.3%).
Quest Diagnostics presents at J.P. Morgan Healthcare Conference; no new financial details disclosed
Presentation at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.
Quest Diagnostics Q3 revenue $2.82B (+13.1%), raises FY2025 adjusted EPS guidance to $9.76–$9.84
Q3 reported diluted EPS $2.16 (+8.5%); adjusted diluted EPS $2.60 (+13.0%) vs $2.30 prior year.
Q2 revenue $2.76B, up 15.2% YoY; organic revenue growth 5.2%.
Quest Diagnostics 2025 meeting: all director nominees elected, exec comp approved
All 10 director nominees elected; highest vote for Robert B. Carter (94.2M for), lowest for Timothy M. Ring (87.2M for).
Quest Diagnostics Q1 revenue up 12.1% to $2.65B, raises FY reported EPS guidance
Q1 net revenues $2.65B (+12.1% YoY); reported diluted EPS $1.94 (+12.8%), adjusted diluted EPS $2.21 (+8.3%).
Long-term outlook: revenue CAGR 4-5%, adjusted EPS CAGR 7-9% beyond 2025.
CEO Jim Davis presented on driving sustainable growth and delivering long-term value.
Q4 revenue $2.62B (+14.5% YoY); reported diluted EPS $1.95 (+14.7%); adjusted diluted EPS $2.23 (+3.7%).
Quest Diagnostics Q3 revenue +8.5% to $2.49B, raises FY revenue guidance
Q3 revenue $2.49B (+8.5% YoY); reported EPS $1.99 (+1.5%); adjusted EPS $2.30 (+3.6%).
Quest Diagnostics closes LifeLabs acquisition; terms not disclosed
Acquisition of LifeLabs Inc., a Canadian lab diagnostics and digital health company, closed on August 26, 2024.
Quest Diagnostics prices $1.85B in senior notes to fund LifeLabs acquisition
Issued $400M at 4.600% due 2027, $600M at 4.625% due 2029, $850M at 5.000% due 2034.
Quest Diagnostics beats Q2 estimates, raises full-year guidance; announces four acquisitions
Q2 revenues $2.397B (+2.5% YoY); reported EPS $2.03 (-1% YoY), adjusted EPS $2.35 (+2.2% YoY)
Quest Diagnostics to acquire LifeLabs from OMERS for C$1.35B (~US$985M)
Cash purchase price of ~C$1.35B (US$985M) including net debt, funded with cash and debt.
Quest Diagnostics shareholders approve officer exculpation, elect directors at annual meeting
Officer exculpation amendment approved with 80.2M for, 13.0M against; effective May 20, 2024.
Quest Diagnostics elects FedEx CIO Robert B. Carter to board; board now 10 members
Robert B. Carter, EVP and CIO of FedEx, elected to Quest's Board effective May 16, 2024.
Quest Diagnostics Q1 revenue $2.37B (+1.5% YoY); raises full-year adjusted EPS to $8.72-$8.97
Revenue $2.366B, up 1.5% YoY; base business revenue grew nearly 6%.
Quest Diagnostics Q4 2023 adjusted EPS $2.15, +8.6%; base business revenue +4.7%
Q4 reported net revenue $2.29B (-1.9% YoY); base business revenue $2.25B (+4.7%).
Quest Diagnostics issues $750M of 6.400% senior notes due 2033
$750M aggregate principal; 6.400% coupon; mature Nov 30, 2033; interest paid semi-annually May 30 & Nov 30.
Quest Diagnostics Q3 revenue $2.30B (-7.7% YoY); adjusted EPS $2.22; base business up 4.6%
Reported diluted EPS $1.96 (down 9.7% YoY); adjusted diluted EPS $2.22 (down 5.9% YoY).
Director Gail R. Wilensky to retire from Quest Diagnostics Board in May 2024
Dr. Gail R. Wilensky notified Quest on Sept 28, 2023 that she will not stand for re-election at the 2024 Annual Meeting.
Quest Diagnostics Q2 revenue $2.34B down 4.7% YoY; base business up 9.5%; raises FY revenue guidance
Q2 reported EPS $2.05 (+4.6% YoY); adjusted EPS $2.30 (-2.5% YoY).
Quest Diagnostics shareholders approve all proposals, reject GHG emissions report
All 10 director nominees elected; James E. Davis received ~86M for, 6M against.
Quest Diagnostics Q1 revenue falls 10.7% to $2.33B; acquires Haystack Oncology for $300M
Q1 net revenue $2.33B, down 10.7% YoY; base business revenue up 10% to $2.21B.
Reiterates 2023 guidance: revenue $8.83B-$9.03B, base business +2.6%-3.8%, adjusted EPS $8.40-$9.00.
Quest CEO James Davis elected Chairman of Board effective April 1
James E. Davis, CEO and President, elected Chairman effective April 1, 2023.
Quest Diagnostics Q4 revenue down 15% to $2.33B; base business up 6.3%; raises dividend 7.6%
Q4 reported net revenues $2.33B (-15% YoY); base business revs $2.15B (+6.3%); COVID revs $184M (-74.6%).
Quest Diagnostics appoints four executive officers to severance plan; amends by-laws
Four executives appointed as executive officers and Schedule B participants in severance plan: Mark Delaney, Mark Gardner, Karthik Kuppusamy, Patrick Plewman (effective Nov 16, 2022).
James E. Davis succeeds Steve Rusckowski as CEO and President effective November 1, 2022.
Quest Diagnostics increases CEO Davis's salary to $1.1M, grants $5M equity upon promotion
CEO Davis base salary raised to $1.1M, target annual incentive 150% of salary, effective Nov 1, 2022.
Q3 2022 net revenues $2.49B, down 10.4% YoY; base business revenues $2.17B, up 5.1% YoY; COVID-19 testing $316M, down 55.4%.
Quest Diagnostics Q2 rev $2.45B (-3.8% YoY); raises FY22 adj EPS guidance to $9.55-$9.95
Q2 reported diluted EPS $1.96 (down 60.5% YoY); adjusted diluted EPS $2.36 (down 25.8% YoY).
Stephen H. Rusckowski retires as CEO/President effective Nov 1, 2022; James E. Davis becomes CEO.
Quest Diagnostics names Sam Samad as EVP & CFO, effective July 25, 2022
Samad joins from Illumina (CFO since 2017); start date July 11, CFO role effective July 25.
Quest Diagnostics SVP Carrie Eglinton Manner resigns effective June 3, 2022
Carrie Eglinton Manner resigns as SVP, Advanced and General Diagnostics and Clinical Solutions.
Quest Diagnostics amends charter to allow written consent, lower special meeting threshold to 15%
Stockholders approved written consent actions with minimum votes needed, replacing prior unanimous consent requirement.
All 10 director nominees elected with majority support; highest vote count 93.2M for Wright Lassiter III.
Quest Diagnostics raises FY2022 guidance after Q1 base business grows 6.3%; adjusted EPS $3.22
Q1 net revenues $2.61B (-4.0% YoY); base business revenues $2.01B (+6.3% YoY); COVID revenues $599M (-27.6%).
Quest Diagnostics director Dr. Helen I. Torley will not seek re-election; board size reduced to 9
Dr. Torley, President & CEO of Halozyme, chose not to stand for re-election at the May 18, 2022 annual meeting.
Quest Diagnostics details CEO-Elect James Davis's 2022 compensation: $800K salary, $4.88M LTI
Base salary $800,000, target annual bonus 100% of salary, LTI award $4,880,649.
CFO Mark Guinan received annual equity grant of $1.12M, half of 2021 grant, with accelerated vesting upon retirement.
On October 6, 2026, Quest Diagnostics Incorporated (the “Company”) announced that Catherine T. Doherty will retire in July 2027.
Until then, effective November 1, 2026, Ms. Doherty will transition to a new role as Executive Vice President with responsibilities including health systems, the Company’s joint venture with Corewell Health, and Project Nova, the Company’s multi-year project to modernize its “Order to Cash” business processes, which includes the related information technology infrastructure and underlying enabling technologies.
On May 16, 2024, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board’s Governance Committee, elected Robert B. Carter to the Board.
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
On November 16, 2022, Mark E. Delaney, Senior Vice President and Chief Commercial Officer; Mark A. Gardner, Senior Vice President, Molecular Genomics and Oncology; Karthik Kuppusamy, Senior Vice President, Clinical Solutions and Patrick T. Plewman, Senior Vice President for Diagnostic Services, became executive officers of Quest Diagnostics Incorporated (the "Company) and became Schedule B participants in the Company's Executive Officer Severance Plan (the "Plan").
Mr. Davis became Chief Executive Officer and President of the Company, and Stephen H. Rusckowski remains Chairman of the Company
Mr. Davis became Chief Executive Officer and President of the Company, and Stephen H. Rusckowski remains Chairman of the Company
elected James E. Davis to fill the resulting vacancy
On October 28, 2022, the Compensation Committee (the “Committee”) of the Board of Directors of Quest Diagnostics Incorporated (the “Company”) approved an updated compensation package for Mr. Davis, reflecting Mr. Davis becoming Chief Executive Officer and President of the Company.
Mr. Rusckowski’s arrangements in connection with his retirement as Chief Executive Officer and President on November 1, 2022 and his service as Executive Chairman of the Company until March 31, 2023.
Max materiality 0.85 · Median 0.68 · Most common event earnings